704 related articles for article (PubMed ID: 19962667)
1. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
Hedvat M; Huszar D; Herrmann A; Gozgit JM; Schroeder A; Sheehy A; Buettner R; Proia D; Kowolik CM; Xin H; Armstrong B; Bebernitz G; Weng S; Wang L; Ye M; McEachern K; Chen H; Morosini D; Bell K; Alimzhanov M; Ioannidis S; McCoon P; Cao ZA; Yu H; Jove R; Zinda M
Cancer Cell; 2009 Dec; 16(6):487-97. PubMed ID: 19962667
[TBL] [Abstract][Full Text] [Related]
2. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Yan S; Li Z; Thiele CJ
Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
[TBL] [Abstract][Full Text] [Related]
5. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
6. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
7. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
Couto JP; Almeida A; Daly L; Sobrinho-Simões M; Bromberg JF; Soares P
PLoS One; 2012; 7(10):e46869. PubMed ID: 23056499
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.
Gu L; Talati P; Vogiatzi P; Romero-Weaver AL; Abdulghani J; Liao Z; Leiby B; Hoang DT; Mirtti T; Alanen K; Zinda M; Huszar D; Nevalainen MT
Mol Cancer Ther; 2014 May; 13(5):1246-58. PubMed ID: 24577942
[TBL] [Abstract][Full Text] [Related]
12. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
Nam S; Wen W; Schroeder A; Herrmann A; Yu H; Cheng X; Merz KH; Eisenbrand G; Li H; Yuan YC; Jove R
Mol Oncol; 2013 Jun; 7(3):369-78. PubMed ID: 23206899
[TBL] [Abstract][Full Text] [Related]
14. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
[TBL] [Abstract][Full Text] [Related]
15. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
16. JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
Fu LX; Lian QW; Pan JD; Xu ZL; Zhou TM; Ye B
J Biol Regul Homeost Agents; 2017; 31(1):51-58. PubMed ID: 28337870
[TBL] [Abstract][Full Text] [Related]
17. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
20. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.
Houghton PJ; Kurmasheva RT; Lyalin D; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2014 Nov; 61(11):1972-9. PubMed ID: 25131802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
